Baricitinib: oral rheumatoid arthritis treatment in new drug class

Olumiant (baricitinib) 4mg tablets are now available for the treatment of moderate-to-severe active rheumatoid arthritis (RA).

Baricitinib improved the signs and symptoms of RA compared with standard therapies. | iStock
Baricitinib improved the signs and symptoms of RA compared with standard therapies. | iStock

Olumiant may be used as monotherapy or in combination with methotrexate in adults who have responded inadequately to or who are intolerant to disease-modifying antirheumatic drugs (DMARDs).

Together with Xeljanz (tofacitinib), Olumiant represents a new class of RA treatments known as JAK inhibitors.

Janus kinase inhibitors

There are four known Janus kinase (JAK) enzymes. Baricitinib is a reversible inhibitor of JAK1 and JAK2, which are widely expressed and mediate signalling of multiple cytokines implicated in the pathogenesis of RA, including interleukin-6, granulocyte-macrophage colony-stimulating factor and interferons.

Phase III trials

Phase III trials of baricitinib comprised four completed studies in a range of adults with RA, from treatment-naïve to inadequate responders to TNF inhibitors. Results showed significant improvements in the signs and symptoms of RA in patients who received baricitinib compared with those who received standard of care therapies such as methotrexate and adalimumab.

RA-BEGIN compared baricitinib, as monotherapy or combined with methotrexate, with methotrexate monotherapy in 588 RA patients. Baricitinib monotherapy was superior to methotrexate monotherapy at week 24, with a higher ACR20 response rate (77% vs 62%, p≤0.01). Similar results were observed for combination therapy.

RA-BEAM was a placebo- and adalimumab-controlled trial of baricitinib plus methotrexate in 1307 RA patients with an inadequate response to methotrexate. Baricitinib showed greater clinical benefits than placebo or adalimumab at week 12, according to ACR20 response rate.

RA-BUILD was a placebo-controlled 24-week study in 684 RA patients with an inadequate response or intolerance to one or more conventional DMARDs. More patients achieved an ACR20 response at week 12 with baricitinib 4mg than placebo. Compared with placebo, statistically significant improvements in Disease Activity Score (DAS28), Simplified Disease Activity Index (SDAI) remission, Health Assessment Questionnaire-Disability Index, morning joint stiffness, worst joint pain and worst tiredness were also observed.

RA-BEACON study was a placebo-controlled trial of baricitinib in 527 RA patients with an inadequate response to biologic DMARDs. Treatment with baricitinib 4mg significantly improved most outcomes at 12 weeks compared with placebo.

Safety profile

The most frequent adverse events seen with baricitinib during trials were increases in LDL-cholesterol, upper respiratory tract infections and nausea. The risks and benefits of treatment should be carefully considered before initiating therapy in patients with active, chronic or recurrent infections. Lipids should be assessed 12 weeks after starting treatment.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.